Add time:07/17/2019         Source:sciencedirect.com

Previous experiments have demonstrated that the intermediary metabolite 6-hydroxymethylbenzo[a] pyrene (HMBP) can be activated to the electrophilic mutagen, 6-sulfooxymethylbenzo[a]pyrene (SMBP), by rat and mouse liver PAPS-dependent sulfotransferase activity or by chemical synthesis. This aralkylating metabolite and 6-hydroxymethylbenzo[a]pyrene were individually administered to groups of 12 female Sprague-Dawley rats, at a 0.2 μmol dose three times weekly for 20 doses. SMBP induced sarcomas at the site of injection in 12 of 12 rats by 33 weeks, whereas HMBP induced sarcomas at the site of injection in 12 of 12 rats by 31 weeks. These results, taken together with the results of previous studies, strongly support the hypothesis that the electrophilic mutagen SMBP accounts for most, if not all, of the complete carcinogenicity of the intermediary metabolite HMBP and probably at least some of the complete carcinogenicity of 6-methylbenzo[a]pyrene (MBP), 6-formylbenzo[a]pyrene (formylBP), and even benzo[a]pyrene (BP), all of which are metabolized to HMBP.

We also recommend Trading Suppliers and Manufacturers of 6-FORMYLBENZO(A)PYRENE (cas 13312-42-0). Pls Click Website Link as below: cas 13312-42-0 suppliers